November 6, 2024
Cytek Biosciences Reports Third Quarter 2024 Financial Results
FREMONT, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell…
Pharmaceuticals, Biotechnology and Life Sciences
FREMONT, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell…
EMERYVILLE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing…
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Nov. 05, 2024 (GLOBE…
— Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate…
New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs…
Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to…
Wide-ranging A*STAR and SERI partnership will accelerate the development of novel developmental candidates in the areas of ophthalmology and oncology,…
MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement…
SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical…
PDUFA target action date set for December 20, 2024THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc.…